<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238715</url>
  </required_header>
  <id_info>
    <org_study_id>E7090-J000-201</org_study_id>
    <nct_id>NCT04238715</nct_id>
  </id_info>
  <brief_title>A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion</brief_title>
  <official_title>A Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by
      Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review
      (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed
      gemcitabine-based combination chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>From first dose of study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.3 years)</time_frame>
    <description>The ORR will be assessed by IIR based on RECIST version 1.1. ORR is defined as a percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). CR: disappearance of all lesions. PR: For PR, longest diameter will be used for non-lymph target lesions but short axis is measured for lymph lesions. PR: greater than or equal to (&gt;=) 30 percent (%) decrease in sum of diameters of target lesions taking as reference baseline, associated to non-progressive disease (non-PD) response for non-target (NT) lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From the date of first dose to the date of first documentation of disease progression or date of death from any cause, whichever occurs first (up to approximately 2.3 years)</time_frame>
    <description>PFS will be assessed by IIR based on RECIST version 1.1. PFS is defined as the time from the date of first dose to the date of first documentation of disease progression or date of death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the date of first documentation of CR or PR to the date of first documentation of disease progression or date of death from any cause, whichever occurs first (up to approximately 2.3 years)</time_frame>
    <description>DOR will be assessed by IIR based on RECIST version 1.1. DOR is defined as the time from the date of first documentation of CR or PR to the date of first documentation of disease progression or date of death from any cause, whichever occurs first. CR: disappearance of all lesions. PR: For PR, longest diameter will be used for non-lymph target lesions but short axis is measured for lymph lesions. PR: greater than or equal to &gt;=30% decrease in sum of diameters of target lesions taking as reference baseline, associated to non-PD response for NT lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>from the date of first study dose to the date of first documentation of CR or PR (up to approximately 2.3 years)</time_frame>
    <description>TTR will be assessed by IIR based on RECIST version 1.1. TTR is defined as the time from the date of first study dose to the date of first documentation of CR or PR. CR: disappearance of all lesions. PR: For PR, longest diameter will be used for non-lymph target lesions but short axis is measured for lymph lesions. PR: greater than or equal to &gt;=30% decrease in sum of diameters of target lesions taking as reference baseline, associated to non-PD response for NT lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of first dose to the date of death from any cause (up to approximately 2.3 years)</time_frame>
    <description>OS is defined as the time from the date of first dose to the date of death from any cause. For the participants who are alive or unknown, OS is censored as the date of last known alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From first dose of study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.3 years)</time_frame>
    <description>DCR will be assessed by IIR based on RECIST version 1.1. DCR is defined as a percentage of participants with BOR of CR, PR or stable disease (SD). The BOR of SD has to be observed greater than or equal to (&gt;=) 7 weeks from the date of first study dose. CR: disappearance of all lesions. PR: For PR, longest diameter will be used for non-lymph target lesions but short axis is measured for lymph lesions. PR: greater than or equal to &gt;=30% decrease in sum of diameters of target lesions taking as reference baseline, associated to non-PD response for NT lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>From first dose of study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.3 years)</time_frame>
    <description>CBR will be assessed by IIR based on RECIST version 1.1. CBR is defined as a percentage of participants with BOR of CR, PR or durable SD (dSD) (duration of SD &gt;=23 weeks). CR: disappearance of all lesions. PR: For PR, longest diameter will be used for non-lymph target lesions but short axis is measured for lymph lesions. PR: greater than or equal to &gt;=30% decrease in sum of diameters of target lesions taking as reference baseline, associated to non-PD response for NT lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>E7090 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7090</intervention_name>
    <description>E7090 tablets orally.</description>
    <arm_group_label>E7090 140 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with a histologically or cytologically diagnosis of intrahepatic or
             perihilar cholangiocarcinoma who agree to provide archival tumor sample or residual
             biopsy sample, or agree with tumor biopsy

          2. Participants who have confirmed FGFR2 gene fusion of tumor by fluorescence in situ
             hybridization (FISH) in central laboratory. FGFR2 gene fusion confirmed by the same
             FISH assay in another test/study will be discussed with the sponsor and agreed on a
             case by case basis

          3. Participants with surgically unresectable or advanced/metastatic disease who have
             received at least one prior chemotherapy including gemcitabine-based combination
             chemotherapy (example: gemcitabine and cisplatin)

          4. Measurable disease meeting the following criteria:

               1. At least 1 lesion of &gt;=1.0 centimeter (cm) in the longest diameter for a
                  non-lymph node or &gt;=1.5 cm in the short-axis diameter for a lymph node that is
                  serially measurable according to RECIST 1.1 using computerized
                  tomography/magnetic resonance imaging (CT/MRI).

               2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
                  such as radiofrequency (RF) ablation must show evidence of progressive disease
                  based on RECIST 1.1 to be deemed a target lesion.

          5. Corrected serum calcium less than or equal to (&lt;=) upper limit of normal (ULN)

          6. Phosphate &lt;=ULN

          7. Participants with Performance Status (PS) score of 0-1 established by Eastern
             Cooperative Oncology Group (ECOG)

          8. Participants who are expected to survive for 3 months or longer after starting
             administration of the investigational drug

          9. Washout period required from the end of prior treatment to the start of E7090
             administration will be as follows

               1. Antibody and other investigational drugs : &gt;=4 weeks

               2. Prior chemotherapy (except small-molecule targeted therapy), surgical therapy,
                  radiation therapyï¼š&gt;=3 weeks

               3. Endocrine therapy, immunotherapy, small-molecule targeted therapy: &gt;=2 weeks

        Exclusion Criteria:

          1. Participants with brain or subdural metastases are not eligible, unless they have
             completed local therapy and have discontinued the use of corticosteroids for this
             indication for at least 4 weeks before starting treatment in this study. Any signs
             (example: radiologic) or symptoms of brain metastases must be stable for at least 4
             weeks before starting study treatment.

          2. Concomitant active infection requiring systemic treatment (except hepatitis B or C
             virus-infected participants who are under anti-viral treatment)

          3. Participants who test positive for human immunodeficiency virus (HIV antibody) at
             Screening 2

          4. Child-Pugh score B or C

          5. Moderate or severe ascites extending from the pelvis to the liver surface

          6. Following ocular disorders.

               1. Current evidence of Grade 2 or higher corneal disorder

               2. Current evidence of active macula disorder (example: age-related macular
                  degeneration, central serous chorioretinal disease)

          7. Participants whose toxicity of previous treatment has not recovered to Grade 1 or
             lower per Common Terminology Criteria for Adverse Events (CTCAE v4.03), except for
             alopecia, infertility and the adverse events listed in inclusion criteria.

          8. Participants with prior therapy targeting FGFR2.

          9. Participants who need the use of drugs or foods that strongly inhibits or induces the
             metabolizing enzyme cytochrome P450 (CYP) 3A4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inquiry Service.</last_name>
    <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site 10</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 16</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 11</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 14</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 2</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 8</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 7</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 13</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 9</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 5</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 4</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 6</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 3</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Ube-Shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 15</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 12</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7090</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Unresectable cholangiocarcinoma</keyword>
  <keyword>Metastatic cholangiocarcinoma</keyword>
  <keyword>Fibroblast Growth Factor Receptor 2 (FGFR2)</keyword>
  <keyword>FGFR2 gene fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

